Warts Treatment Pipeline Review H2 2016

Warts - Pipeline Review, H2 2016

PUNE, INDIA, August 30, 2016 /EINPresswire.com/ -- Summary
Warts - Pipeline Review, H2 2016’, provides an overview of the Warts pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Warts, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Warts and features dormant and discontinued projects.

Complete report details @ https://www.wiseguyreports.com/reports/619289-warts-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ https://www.wiseguyreports.com/sample-request/619289-warts-pipeline-review-h2-2016

- The report provides a snapshot of the global therapeutic landscape of Warts
- The report reviews pipeline therapeutics for Warts by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Warts therapeutics and enlists all their major and minor projects
- The report assesses Warts therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Warts
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Warts
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Warts pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/619289-warts-pipeline-review-h2-2016

Key points in table of content
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Warts Overview 9
Therapeutics Development 10
Pipeline Products for Warts - Overview 10
Warts - Therapeutics under Development by Companies 11
Warts - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Warts - Products under Development by Companies 15
Warts - Companies Involved in Therapeutics Development 17
3M Drug Delivery Systems 17
Aclaris Therapeutics, Inc. 18
Agilvax, Inc. 19
Aviragen Therapeutics, Inc. 20
Biogenomics Limited 21
BioMAS Ltd. 22
Cytovation AS 23
Foamix Pharmaceuticals Ltd. 24
G&E Herbal Biotechnology Co., Ltd. 25
Laboratories Ojer Pharma S.L. 26
LEO Pharma A/S 27
Nielsen Biosciences, Inc. 28
Novan, Inc. 29
Novartis AG 30
Promius Pharma, LLC 31
RXi Pharmaceuticals Corporation 32
Tamir Biotechnology, Inc. 33
Verrica Pharmaceuticals Inc. 34
Zydus Cadila Healthcare Limited 35
Warts - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
(cervical cancer + genital warts) vaccine - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
(digoxin + furosemide) - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
854-A - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
AS-101 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
AX-03 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
BTA-074 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Candida Albicans Antigen - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
CyPep-1 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
DFD-05 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
diphencyprone - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
FIT-039 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
hydrogen peroxide - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
imiquimod - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
imiquimod SR - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
ingenol mebutate - Drug Profile 65
Product Description 65
Mechanism Of Action 65

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619289

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here